ERBB2 and breast neoplasm: However, neither the taxane or the anti-HER2 antibody have been loaded to PDA NPs to date, and the resulting drug delivery NPs have been shown to reduce normal cell viability rate to a lesser extent than the parent drug and to have a very remarkable antitumor activity in vitro, not only in HER2+ conventional cell cultures, but also in breast tumor spheroids.